Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LIPIL for Moms

This article was originally published in The Tan Sheet

Executive Summary

Expecta LIPIL supplements for pregnant and nursing women are reaching shelves this month, Mead Johnson says. The softgel capsules contain Martek Biosciences' docosahexaenoic acid (DHA) that helps "support your baby's brain and eye development," according to Mead. Expecta LIPIL will be sold at Target, Walgreens and Albertsons in 30-count boxes for between $10.89 and $11.99. Mead Johnson will promote the product through print ads in magazines such as Baby Talk, Healthy Pregnancy and New Parent, as well as OB/GYN and pediatricians' offices...

You may also be interested in...



In Brief

Novartis ships Excedrin Migraine; Perrigo will launch mini nicotine lozenges; Matrixx ups offer to buy ProPhase; Merck consolidates HQ in Summit, N.J.; NBTY expects at least 3% sales boost; FDA will hold risk communication meeting; more news In Brief.

In Brief

Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.

In Brief

Appropriations subcommittee largely ignores FDA; analysts predict lower Novartis OTC sales; France tightens advertising rules; NAD weighs in on Lunada claims; Global Biotechnologies supplements seized; Tetley tea faces lawsuit for antioxidant claims; more news In Brief.

Related Content

Topics

UsernamePublicRestriction

Register

PS097432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel